Filing Details
- Accession Number:
- 0001209191-11-057247
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2011-11-18 20:01:31
- Reporting Period:
- 2011-11-16
- Filing Date:
- 2011-11-18
- Accepted Time:
- 2011-11-18 20:01:31
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
858803 | Avanir Pharmaceuticals Inc. | AVNR | Pharmaceutical Preparations (2834) | 330314804 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1314596 | Keith Katkin | 20 Enterprise, Suite 200 Aliso Viejo CA 92656 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2011-11-16 | 109,013 | $0.53 | 317,365 | No | 4 | M | Direct | |
Common Stock | Disposition | 2011-11-16 | 109,013 | $2.59 | 208,352 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2011-11-17 | 2,587 | $0.53 | 210,939 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2011-11-17 | 106,425 | $0.88 | 317,364 | No | 4 | M | Direct | |
Common Stock | Disposition | 2011-11-17 | 109,012 | $2.59 | 208,352 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock option (right to buy) | Disposition | 2011-11-16 | 109,013 | $0.00 | 109,013 | $0.53 |
Common Stock | Stock option (right to buy) | Disposition | 2011-11-17 | 2,587 | $0.00 | 2,587 | $0.53 |
Common Stock | Stock option (right to buy) | Disposition | 2011-11-17 | 106,425 | $0.00 | 106,425 | $0.88 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
142,087 | 2018-12-16 | No | 4 | M | Direct | |
139,500 | 2018-12-16 | No | 4 | M | Direct | |
319,275 | 2018-07-25 | No | 4 | M | Direct |
Footnotes
- Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting Person, which are subject to certain vesting conditions.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.56 to $2.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Following the sales reported on this Form 4, the Reporting Person has a total of 862,204 options to purchase shares of common stock that are vested and immediately exercisable and 1,012,412 options to purchase shares of common stock that have not yet vested. Following the sales reported on this Form 4, the Reporting Person also has 62,500 unvested Restricted Stock Units.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.55 to $2.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- The option vested with respect to one-quarter of the underlying shares upon the first anniversary of the grant date, and then with respect to the remaining shares quarterly thereafter over the next three years.
- The option vested with respect to 6.25% of the underlying shares upon the achievement of certain performance goals and continues to vest on a quarterly basis over 15 quarters from the initial vesting of the 6.25% upon the achievement of the performance goals.